Company intelligence / Profile preview
Alizyme
Cambridge, Cambridgeshire, United Kingdomalizyme.com ↗
- Ownership
- Private
- Employees
- ~10-50
- Development stage
- Other
01
Overview
Alizyme was a drug development company that had several products in clinical trials, including Renzapride for IBS-C (failed Phase III), Cetilistat for obesity, COLAL-PRED for ulcerative colitis (failed to meet efficacy targets in Phase III), and ATL-104 for mucositis (Phase IIa). The company went into administration in 2009 after failing to raise sufficient funds.
- Therapeutic areas
- GastroenterologyEndocrinology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Takeda Pharmaceutical Company LtdNorgine BV
Beyond the preview
Go deeper on Alizyme.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alizyme.